Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upamostat
- Development stage
- Phase 3
- Lead developer
- RedHill Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Upamostat (RHB-107) is an orally bioavailable, first-in-class serine protease inhibitor originally developed by Heidelberg Pharma (formerly WILEX AG) and currently being developed by RedHill Biopharma. It acts as a prodrug of WX-UK1, targeting several human serine proteases including urokinase-type plasminogen activator (uPA), matriptase, and transmembrane protease serine 2 (TMPRSS2). By inhibiting these host-cell proteases, upamostat prevents viral entry (relevant for COVID-19 and potentially Ebola) and interferes with tumor cell invasion and metastasis. It is primarily being evaluated for the early outpatient treatment of COVID-19 in the Phase 2 ACESO PROTECT trial and has historical development in various cancers and inflammatory gastrointestinal diseases.
- Brand names
- Mesupron
- Other names
- upamostat
02
Targets
CTSL (Cathepsin L)PRSS3 (Trypsin-3)PLAU (uPA)TTSP (Type II transmembrane serine protease)PRSS2 (Trypsin-2)
Beyond the preview
Go deeper on upamostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upamostat.